Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMNM Immunome Inc
- Stocks
- Healthcare
- NASDAQ: IMNM
Price (delayed)
$8.06
Market cap
$701.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.18
Enterprise value
$448.38M
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are
Highlights
Immunome's quick ratio has surged by 158% QoQ and by 2.4% YoY
The equity has soared by 70% from the previous quarter and by 8% YoY
Immunome's gross profit has increased by 21% QoQ but it has decreased by 14% YoY
The revenue rose by 21% QoQ but it fell by 14% YoY
Key stats
What are the main financial stats of IMNM
Market
Valuations
Earnings
Shares outstanding
87.01M
Market cap
$701.32M
Enterprise value
$448.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.28
Price to sales (P/S)
58.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.99
Revenue
$10.94M
Gross profit
$10.94M
Operating income
-$218.14M
Net income
-$205.11M
EBIT
-$205.11M
EBITDA
-$202.55M
Free cash flow
-$161.35M
Per share
Balance sheet
Liquidity
EPS
-$3.18
EPS diluted
-$3.18
Free cash flow per share
-$2.03
Book value per share
$3.53
Revenue per share
$0.14
TBVPS
$4.32
Total assets
$342.69M
Total liabilities
$35.57M
Debt
$4.77M
Equity
$307.13M
Working capital
$292.33M
Debt to equity
0.02
Current ratio
10.49
Quick ratio
10.31
Net debt/EBITDA
1.25
Margins
Efficiency
Dividend
EBITDA margin
-1,851.8%
Gross margin
100%
Net margin
-1,875.2%
Operating margin
-1,994.3%
Return on assets
-72.2%
Return on equity
-85.7%
Return on invested capital
-311.1%
Return on capital employed
-65.8%
Return on sales
-1,875.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNM stock price
How has the Immunome stock price performed over time
Intraday
0.75%
1 week
8.04%
1 month
12.41%
1 year
-44.03%
YTD
-24.11%
QTD
19.76%
Financial performance
How have Immunome's revenue and profit performed over time
Revenue
$10.94M
Gross profit
$10.94M
Operating income
-$218.14M
Net income
-$205.11M
Gross margin
100%
Net margin
-1,875.2%
IMNM's net margin is up by 42% since the previous quarter but it is down by 2.5% year-on-year
Immunome's operating margin has increased by 41% from the previous quarter but it has decreased by 7% YoY
IMNM's net income is up by 30% since the previous quarter and by 12% year-on-year
Immunome's operating income has increased by 29% QoQ and by 8% YoY
Price vs fundamentals
How does IMNM's price correlate with its fundamentals
Growth
What is Immunome's growth rate over time
Valuation
What is Immunome stock price valuation
P/E
N/A
P/B
2.28
P/S
58.52
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
40.99
IMNM's EPS has soared by 58% YoY and by 36% QoQ
The equity has soared by 70% from the previous quarter and by 8% YoY
The price to book (P/B) is 51% lower than the 5-year quarterly average of 4.7 and 26% lower than the last 4 quarters average of 3.1
The revenue rose by 21% QoQ but it fell by 14% YoY
IMNM's price to sales (P/S) is 14% lower than its last 4 quarters average of 68.0
Efficiency
How efficient is Immunome business performance
The ROIC has soared by 98% YoY and by 40% from the previous quarter
Immunome's ROE has soared by 61% YoY and by 32% from the previous quarter
The company's return on assets has surged by 53% YoY and by 31% QoQ
IMNM's ROS is up by 42% QoQ but it is down by 2.5% YoY
Dividends
What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNM.
Financial health
How did Immunome financials performed over time
Immunome's quick ratio has surged by 158% QoQ and by 2.4% YoY
The current ratio has soared by 157% QoQ and by 3% YoY
IMNM's debt is 98% smaller than its equity
The equity has soared by 70% from the previous quarter and by 8% YoY
Immunome's debt to equity has decreased by 33% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.